From the Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Neurology. 2020 Aug 11;95(6):e708-e717. doi: 10.1212/WNL.0000000000010028. Epub 2020 Jul 7.
To determine whether increased risk of acute ischemic stroke (AIS) following herpes zoster (HZ) might be modified by the status of zoster vaccine live (ZVL) vaccination and antiviral treatment following HZ.
We included 87,405 Medicare fee-for-service beneficiaries aged ≥66 years diagnosed with HZ and AIS from 2008 to 2017. We used a self-controlled case series design to examine the association between HZ and AIS, and estimated incidence rate ratios (IRRs) by comparing incidence of AIS in risk periods vs control periods. To examine effect modification by ZVL and antiviral treatment, beneficiaries were classified into 4 mutually exclusive groups: (1) no vaccination and no antiviral treatment; (2) vaccination only; (3) antiviral treatment only; and (4) both vaccination and antiviral treatment. We tested for interaction to examine changes in IRRs across 4 groups.
Among 87,405 beneficiaries with HZ and AIS, 22.0%, 2.0%, 70.1%, and 5.8% were in groups 1 to 4, respectively. IRRs in 0-14, 15-30, 31-90, and 91-180 days following HZ were 1.89 (95% confidence interval [CI], 1.77-2.02), 1.58 (95% CI, 1.47-1.69), 1.36 (95% CI, 1.31-1.42), and 1.19 (95% CI, 1.15-1.23), respectively. There was no evidence of effect modification by ZVL and antiviral treatment on AIS ( = 0.067 for interaction). The pattern of association between HZ and risk for AIS was largely consistent across age group, sex, and race.
Risk of AIS increased significantly following HZ, and this increased risk was not modified by ZVL and antiviral treatment. Our findings suggest the importance of following recommended HZ vaccination in prevention of HZ and HZ-associated AIS.
确定带状疱疹(HZ)后发生急性缺血性脑卒中(AIS)的风险增加是否可通过 ZVL 疫苗接种和 HZ 后抗病毒治疗的状态来改变。
我们纳入了 2008 年至 2017 年期间年龄≥66 岁、被诊断为 HZ 和 AIS 的 87405 名医疗保险按服务收费受益人群。我们使用自我对照病例系列设计来检查 HZ 与 AIS 之间的关联,并通过比较风险期与对照期内 AIS 的发生率来估计发病率比值比(IRR)。为了检验 ZVL 和抗病毒治疗的作用修饰,将受益人群分为 4 个互斥组:(1)无疫苗接种和无抗病毒治疗;(2)仅疫苗接种;(3)仅抗病毒治疗;(4)疫苗接种和抗病毒治疗均有。我们进行了交互检验,以检查 4 组之间 IRR 的变化。
在 87405 名患有 HZ 和 AIS 的受益人群中,分别有 22.0%、2.0%、70.1%和 5.8%的人群在组 1 到组 4。HZ 后 0-14、15-30、31-90 和 91-180 天的 IRR 分别为 1.89(95%置信区间[CI],1.77-2.02)、1.58(95%CI,1.47-1.69)、1.36(95%CI,1.31-1.42)和 1.19(95%CI,1.15-1.23)。ZVL 和抗病毒治疗对 AIS 无明显的修饰作用(交互检验的=0.067)。HZ 与发生 AIS 的风险之间的关联模式在年龄组、性别和种族之间基本一致。
HZ 后 AIS 的风险显著增加,且这种风险增加不受 ZVL 和抗病毒治疗的影响。我们的研究结果表明,遵循推荐的 HZ 疫苗接种方案预防 HZ 和 HZ 相关的 AIS 非常重要。